burger

A pharmaceutical company
specialising in biological
medicinal products

15 medicines

prescribed to

hospital

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

BIOPRODUCTION SITES in the world

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

Group executive committee

Committee’s composition
€ 459 M IN TURNOVER

IN 2021

1 of the leaders in France

IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS

All news

5:01

The fractionation of the LFB plasma-derived medicinal products : 1 plant on 2 sites

2:44

2022 LFB corporate video

3:24

THE NEW LFB ARRAS PLANT, January 2022

3:00

LFB alongside the ADAAT association

All videos

LFB GOVERNANCE CHANGE: Jacques Brom is appointed CEO of LFB

LFB announces the approval of CEVENFACTA® in the European Union

2022 LFB Corporate video

Discover the new LFB CSR Charter

LFB and Kedrion sign an industrial cooperation agreement to supply immunoglobulins in France

Interview with Denis Delval

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

5:01

The fractionation of the LFB plasma-derived medicinal products : 1 plant on 2 sites

there is 2 months

2:44

2022 LFB corporate video

there is 6 months

3:24

THE NEW LFB ARRAS PLANT, January 2022

there is 10 months

3:00

LFB alongside the ADAAT association

there is 1 year